U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07180186) titled 'Microbiota and Probiotic Therapy in Ulcerative Colitis Patients' on Sept. 11.
Brief Summary: This study aimed to evaluate the role of microbiota and probiotics in Egyptian patients with ulcerative colitis.
Study Start Date: Jan. 01, 2022
Study Type: OBSERVATIONAL
Condition:
Microbiota
Probiotic Therapy
Ulcerative Colitis
Intervention:
DRUG: Mesalamine
Patients with ulcerative colitis in remission treated with oral mesalamine.
DRUG: Probiotics (Bacillus Clausii)
Patients with ulcerative colitis in remission treated with probiotics (Bacillus Clausii).
DRUG: Mesalamine and probiotics (Bacillus Clausii)
Patients with ulcerat...